✦ LIBER ✦

Human Dendritic Cell Subsets for Vaccination

✍ Scribed by Peter Dubsky; Hideki Ueno; Bernard Piqueras; John Connolly; Jacques Banchereau; A. Karolina Palucka

Publisher: Springer
Year: 2005
Tongue: English
Weight: 701 KB
Volume: 25
Category: Article
ISSN: 0271-9142
DOI: 10.1007/s10875-005-8216-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dendritic cell–tumor cell hybrid vaccina

Dendritic cell–tumor cell hybrid vaccination for metastatic cancer

✍ Jose Alexandre M. Barbuto; Luis F. C. Ensina; Andreia R. Neves; Patrícia C. Berg 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 285 KB

Dendritic cell vaccination and immune mo

Dendritic cell vaccination and immune monitoring

✍ E. H. J. G. Aarntzen; C. G. Figdor; G. J. Adema; C. J. A. Punt; I. J. M. de Vrie 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 477 KB

Toll-like receptor expression and functi

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

✍ Gerty Schreibelt; Jurjen Tel; Kwinten H. E. W. J. Sliepen; Daniel Benitez-Ribas; 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 463 KB

From skin dendritic cells to a simplifie

From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets

✍ Martin Guilliams; Sandrine Henri; Samira Tamoutounour; Laurence Ardouin; Isabell 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB

Dendritic-cell- and peptide-based vaccin

Dendritic-cell- and peptide-based vaccination strategies for glioma

✍ Ryuya Yamanaka 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 190 KB

Dendritic-cell-based therapeutic vaccina

Dendritic-cell-based therapeutic vaccination against cancer

✍ Frank O Nestle; Arpad Farkas; Curdin Conrad 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines, tested different vaccine preparations, but they did not always induce sufficient acquired immunity or meet the expected level of tumor regressions. Current studies aim to improve the DC vaccine approach